Among 455 subjects, the AGTR1 A1166C polymorphism predicted a greater likelihood of prehypertension, and prehypertensive individuals had greater plasma glucose, insulin, and IL-6 than normotensives.
Cohort (n=455)
Are there early inflammatory and metabolic changes, and associations with AGTR1 polymorphisms, in prehypertensive subjects compared to normotensive subjects?
Prehypertensive subjects exhibit early metabolic and inflammatory changes, and the AGTR1 A1166C polymorphism is associated with an increased likelihood of prehypertension.
BACKGROUND: The Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in 2003 created a prehypertension category for persons with blood pressures ranging from systolic blood pressure (SBP) of 120-139 mm Hg or diastolic blood pressure (DBP) from 80 to 89 mm Hg, due to increased risk of cardiovascular disease. METHODS: Our study utilized the University of California-San Diego (UCSD) Twin Hypertension Cohort. We measured comprehensive plasma cholesterol levels and metabolic (glucose, insulin, leptin) and inflammatory markers (interleukin-6 (IL-6), C-reactive protein (CRP), free fatty acids) to determine the differences between normotensive and prehypertensive subjects. Additionally, we determined whether angiotensin II receptor type-1 (AGTR1) polymorphisms, previously associated with hypertension, could predict prehypertension. RESULTS: A total of 455 white subjects were included in the study (mean age 37.1 years). Prehypertensive subjects were older with greater body mass index (BMI) than the normotensives, and after adjusting for sex and age, had greater plasma glucose, insulin, and IL-6. The common AGTR1 A1166C (rs5186) polymorphism in the 3'-UTR region, particularly the presence of the 1166C allele, which fails to downregulate gene expression, predicted greater likelihood of being in the prehypertension group and higher SBP. A lesser-studied polymorphism in intron-2 of AGTR1 (A/G; rs2276736) was associated with plasma high-density lipoprotein (HDL) and apolipoprotein A-1. In a subgroup analysis of nonobese subjects (N = 405), similar associations were noted. CONCLUSION: Prehypertensive subjects already exhibit early pathophysiologic changes putting them at risk of future cardiovascular disease, and AGTR1 may also contribute to this increased risk. Further investigation is needed to confirm these findings and the precise molecular mechanisms of action.
Fung et al. (Thu,) conducted a cohort in Prehypertension (n=455). AGTR1 polymorphisms vs. Absence of polymorphism / Normotensive subjects was evaluated on Differences in metabolic and inflammatory markers and prediction of prehypertension. Among 455 subjects, the AGTR1 A1166C polymorphism predicted a greater likelihood of prehypertension, and prehypertensive individuals had greater plasma glucose, insulin, and IL-6 than normotensives.